Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              patrik.dehaes@thrombogenics.com
    Chris Buyse, CFO                          Tel: +32-16-75-13-10
                                              chris.buyse@thrombogenics.com
    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71
                                              amber.bielecka@citigatedr.co.uk


<
'/>"/>
SOURCE  ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...RNewswire-Asia/--NODPharmaceuticalsInc.announced,t...tentapplicationfor,itsnano-particleoraldeliveryorN...ntapproachtoincorporatepeptidesor,proteinsintobio-...otherwiseadministeredasinjections.NODtechnologyisa...culardrugssuchasinsulin,interferon,growthhormone,...
(Date:11/24/2009)...Newswire/--BlueMarbleEnergyCorp.announcedtodaythat...PDA)wererecentlyawarded$2millionbyWashingtonState,...ate/publicpartnershiptoconstructthestate,sfirstspe..., "Thisinvestmentwillsignificantlyspeedthedevelo...olnCounty,"saidBlueMarbleEnergyCEOKellyOgilvie."We...
(Date:11/24/2009)..., TORONTO,Nov.24/PRNewswire-FirstCall/-Hamilton...leadingproviderofadvancedlasersystemsandinstrument...odayreportedoperationalandfinancialresultsfortheth...hts,-Revenuewas$1.46millioncomparedwith$1.43milli...dwith66.1percentinQ3,2008,-Netlossreducedto$148,00...
(Date:11/24/2009)....,Nov.24/PRNewswire-FirstCall/--GenomicHealth,Inc....cHealth,sExecutiveChairman,willpresentatthe21stAnn...Tuesday,December1,2009at10:00a.m.ET. ,, Toacces...ation,visittheInvestorRelationssectionofGenomicHea...Pleaseconnecttothewebsiteatleast15minutespriortoth...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Genomic Health to Present at Piper Jaffray Health Care Conference 2
... , For purification of up to 10 mg ultrapure... Classic QIAGEN Plasmid Kits use gravity-flow anio...n of plasmid DNA , , , ,... , , Purity equival...ation , , Reprod...
..., , Ni-NTA Superflow Columns enable up to 2...ein preparations to be performed in parallel on th...d lysates from bacterial cultures as starting mate...be purified under native or denaturing , co...e in yield means that , more experiments ca...
..., , Stefanie Schrer, Werner Wittke,* and ,...lden, Germany , , * Leica Microsyst..., Laser microdissection (LMD) provides a powe... or cell groups for further analysis. , Thi...ty within tissue samples , by providing hom...
Other Biology Technology:Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 2Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 3Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 4Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 2Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 3Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 4
(Date:11/24/2009)...een prescribed by traditional healers in Brazil to...ach pain to fever and flu. , Now for the first ti...able to scientifically prove the pain relieving pr...razilian mint. , Testing this ancient South Ameri...ela Rocha was able to show that when prepared as a...
(Date:11/24/2009)...oors to understanding how sounds associated with N...mal or if they hear it at all. , The same type ... uses to detect flaws in the space shuttle,s behem...to peek inside the giant head of a whale. The scan...s of a whale,s hearing anatomy using a breakthroug...
(Date:11/24/2009)...labby arteries from collapsing have been true life... longer needed -- once the arteries are strengthen...ad no choice but to leave them in place. , Prof....ent of Biomedical Engineering has developed a new ...here they,re needed, then dissolves. , "Our new ...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2A coating for life 2Phosphorus Levels May Predict Heart Disease 60795 1Phosphorus Levels May Predict Heart Disease 60795 2Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 1Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 2Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 3Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 4Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 5Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy 28SRT 29 in Diabetic Macular Edema 28DME 29 60791 6Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 1Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 2Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 3Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 4Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 5Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 6Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 7Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 8Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 9Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 10Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 11Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 12Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 13Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 14
...ant to catch a trophy northern pike, walleye or br...ter plan your trip soon. Thats because according ...ation Society, looming development, including fore...pristine region of untouched forests, wetlands, la...so say that that there is still time for governmen...
...s Consortium say they are absolutely delighted by ... to host a new 1billion national institute to deve...s comprised of the universities of Birmingham, Lou...rs, all with extensive and complementary energy re...port has been provided, in a unique cross-border a...
...alth Care through Bio and Information Standards an...he role technology and technical standards can pla...costs. , WHY ATTEND: To learn where technology in...ality, wellness and disease prevention, while mini...a.m. to 5:30 p.m. , WHERE: National Institute of...
Other Biology News:Canada's pristine freshwater fisheries at risk 2Canada's pristine freshwater fisheries at risk 3Midlands Consortium delighted to be chosen to host £1 billion energy institute 2Midlands Consortium delighted to be chosen to host £1 billion energy institute 3
Rabbit Anti-Human TRIB1 / SKIP1 / Tribbles 1 Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-Pim-1 Monoclonal Antibody, Unconjugated, Clone 12H8 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-Human Ets-1 Antibody, Unconjugated from Spring Bioscience
Mouse Anti-Desmoglein 1 Monoclonal Antibody, Unconjugated, Clone 3G131 from Abcam
Biology Products: